Drug development of promising hits from phenotypic screens is often hampered due to a lack of information on the cellular target or the mode of action of the compound. An efficient method for target identification is chemogenomic profiling in the surrogate model Saccharomyces cerevisiae. Here we briefly review the progress of this technology, give some successful target identification examples and present future directions for haploinsufficiency and homozygous profiling in higher eukaryotes based on the CRISPR-Cas9 system.
Verena Pries and Dominic Hoepfner
Cellular & Molecular Medicine: Open access received 187 citations as per google scholar report